Loading company…
Peroxitech Therapeutics develops treatments for acute lung injury.
Peroxitech Therapeutics is developing PIP-2, a lead molecule intended to address acute lung injury and reduce reactive oxygen species buildup in the lungs. The biopharmaceutical company is based in Pennsylvania, US. It raised seed funding led by Xontogeny, LCC in May 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in